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external agents, lung involvement in non-pulmonary conditions,
or miscellaneous diseases of the lung/respiratory system. Study
measures were assessed over four time periods: 0–12 months pre-
and post-index, 13–24 months post-index, and 25+ months post-
index. Costs of IPF, pulmonary disease (ICD-9-CM 480–519),
and all healthcare services were estimated by category of
resource use. RESULTS: A total of 896 met all patient selection
criteria. They had a mean (SD) age of 48.1 (22.2) years, about
60% were female, and about 44% were white. Approximately
14% of patients died within 12 months of their index date Mean
monthly costs of IPF-related care varied from $148–$314
depending on the follow-up period. Mean monthly costs of all
patient care were more than $4000 higher among IPF versus
non-IPF patients in Florida Medicaid ($4360 vs. $315). CON-
CLUSIONS: Per-patient costs of IPF appear to be considerable
in this population.
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OBJECTIVES: The study evaluated the inﬂuence of tobacco
smoking on direct costs of treatment of chronic obstructive pul-
monary disease (COPD) exacerbations. METHODS: A total of
112 men who underwent treatment of COPD exacerbation in
the Military Institute of Health Service from November 2001 to
October 2002 were included in the study. The patients were qual-
iﬁed into one of three groups: I—never-smoking patients (n =
40), II—former smokers (n = 42); III—active smokers (n = 30).
RESULTS: The mean direct cost of exacerbation treatment was
USD 686.2 (SD 292.3) [group I—642.9 (SD 216.2); group II—
USD 595.4 (SD 193.2); group III—USD 871.1 (SD 401.9)]. No
signiﬁcant differences in treatment costs were found between the
group I and group II. The costs of inhospital treatment of COPD
were signiﬁcantly higher in the group III than in the groups I and
II. A linear correlation was found between each consecutive pack
year of addiction and the costs of exacerbation treatment in the
group III (R = 0.39, R2 = 0.13; p < 0.03). No similar relation-
ship was found in the former smokers’ group. CONCLUSION:
Active tobacco smoking by COPD patients is related to sig-
niﬁcantly higher direct costs of hospitalization due to COPD
exacerbations.
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OBJECTIVES: Assessment of the inﬂuence that a doctor taking
care of a patient has on direct costs of inhospital treatment of
chronic obstructive pulmonary disease (COPD) exacerbation.
METHODS: Medical documentation of patients who had under-
gone treatment of COPD exacerbation in the Military Institute
of Health Service from November 2001 to October 2002 was
studied retrospectively. Direct costs of hospitalization in 8 groups
of patients treated by different doctors (8 specialists, with a
similar length of experience), were compared. RESULTS: A total
of 182 patients were qualiﬁed into 8 study groups, each treated
by a different doctor. The mean hospitalization period was 7.6
(SD 3.1) days. The mean (discounted for 2005) cost of COPD
exacerbation treatment was USD 841.7 (SD 371.0). No statisti-
cally signiﬁcant differences between the groups were found in 
the mean age of the patients, strength of nicotine addiction
(expressed in pack years), severity of the disease and pulmonary
function indices. Differences between the mean direct costs of
treatment by individual doctors amounted to as much as 87%
[USD 690.6 (SD 401.5) vs. USD 1 291.8 (SD 438.6), p < 0.05],
and they resulted mainly from different length of hospitalization
and costs of additional examinations. CONCLUSION: A way of
taking care of a patient by a doctor signiﬁcantly inﬂuences direct
costs of inhospital treatment of COPD exacerbations.
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OBJECTIVES: To assess the cost-effectiveness of Palivizumab, a
prevention against respiratory syncytial virus (RSV) in infants at
high risk, such as premature babies, infants with bronchopul-
monary dysplasia (BPD), and children with congenital heart
disease (CHD) in an Austrian health care setting. METHODS:
A decision tree model was used to estimate the cost-effectiveness
of Palivizumab in high-risk children. The data sources included
published literature, the Palivizumab pivotal trials, ofﬁcial
price/tariff lists and national population statistics. The study was
conducted from the perspective of the health care purchaser
(HCP) (primary) and society (secondary). RESULTS: From the
perspective of the HCP, the incremental cost-effectiveness ratio
(ICER) for preterm infants is €4484/quality adjusted life year
(QALY) without discounting; and becomes €14,439/QALY dis-
counted. For children with BPD the ICER is €6719/QALY
without discounting and increases to €21,672/QALY after dis-
counting. In the CHD indication the ICER is €3115/QALY
undiscounted, while €11,390/QALY discounted. The results
from the society perspective were substantially more cost-effec-
tive in all study populations. In preterm children the ICER is
€1435/QALY without discounting, and becomes €4623/QALY
discounted. For children with BPD the ICER is €4881/QALY
undiscounted and €15,741/QALY after discounting. For the
CHD group the ICER is €251/QALY undiscounted, and
€917/QALY discounted. Sensitivity analyses conﬁrmed the
robustness of the model. CONCLUSION: This study showed
that Palivizumab is a cost-effective prevention against RSV infec-
tions in high-risk infants in Austria under the current health eco-
nomic standards.
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OBJECTIVES: Current treatment guidelines for COPD recom-
mend the use of bronchodilators for the management of patients
with mild to moderate disease and adding inhaled corticosteroids
for severe patients and patients with repeated exacerbations.
This analysis evaluates COPD patients initiating treatment 
with either an inhaled corticosteroid or an anticholinergic to
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determine adherence to treatment guidelines. METHODS: In a
retrospective database study, continuously enrolled patients aged
18 years and older with COPD (COPD only or COPD+asthma),
who initiated therapy during year 2002 with either an inhaled
corticosteroid or an anticholinergic (ﬁrst ﬁll date identiﬁed as
index date) were included in the analyses. The severity of iden-
tiﬁed subjects was determined using two METHODS: respira-
tory disease-related health care utilization; and charlson
comorbid score during the one-year baseline period. Presence of
comorbid conditions was also determined. RESULTS: Of the
8392 patients identiﬁed as having COPD, 467 (5.56%) initiated
an inhaled corticosteroid and 495 (5.90%) initiated an anti-
cholinergic. Using respiratory related healthcare utilization in the
baseline period as a proxy for disease severity, 82% of inhaled
corticosteroid users were low utilizers, 14% were moderate uti-
lizers and 4% were high utilizers whereas 53% of anticholiner-
gic users were low utilizers, 31% were moderate utilizers and
16% were high utilizers. At baseline, mean Charlson comorbid-
ity score was signiﬁcantly lower among inhaled corticosteroid
users (0.88) as compared to anticholinergic users (1.32). Also, at
baseline anticholinergic users had a signiﬁcantly higher percent-
age of patients with comorbid diagnosis of congestive heart
failure, atherosclerosis, coronary heart disease, hypertension,
mental illness and other lung disease. Results were also consis-
tent in the COPD only group. All differences were signiﬁcant at
p < 0.05. CONCLUSIONS: Patients initiating an inhaled cor-
ticosteroid appeared to be less severe as indicated by lower 
health care utilization, lower Charlson comorbid score and 
fewer comorbid conditions than those patients initiated on 
anticholinergics.
URINARY/KIDNEY—Clinical Outcomes Studies
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OBJECTIVE: Neurogenic bladder is a condition that involves
bladder dysfunction caused due to damage to any part of the
nervous system. Patients with neurogenic bladder encounter dif-
ﬁculties such as bladder overactivity, urinary incontinence, and
urge incontinence. The objective of this study was to assess the
prevalence of neurogenic bladder in patients with different neu-
rological conditions. METHODS: A thorough literature search
was performed using MEDLINE and other databases such as
HAPI, OVID, and ScienceDirect. Information related to neuro-
genic bladder, speciﬁcally estimates of proportion of patients suf-
fering from neurogenic bladder was obtained from this search.
Articles that were published between the years 1995–2004 were
included. Percentages obtained from the literature were com-
bined with prevalence data of various neurologic disorders avail-
able on National Center for Health Statistics website to obtain
estimated number of patients with different neurologic condi-
tions suffering from neurogenic bladder. RESULTS: Neurogenic
bladder is found to be most prevalent in patients with Stroke,
Parkinson’s disease, Traumatic Brain injury, Dementia, Spinal
Cord injury, Multiple Sclerosis, Spina Biﬁda and paralysis. It is
found to be prevalent in more than half of patients suffering from
Stroke which is estimated to be more than two million. Its preva-
lence in Parkinson’s patients varies widely between 0.2–0.7
million (27–70%). Occurrence of urinary incontinence due to
neurogenic bladder in patients with Dementia was 11–90%, an
estimate of approximately 0.2–1.5 million, depending on the
setting in which the patients are treated. Bladder overactivity has
been detected in 50–90% of patients with Multiple Sclerosis and
in 95% of patients with Spina Biﬁda, together accounting for an
estimated half million patients. CONCLUSIONS: There is a high
prevalence of bladder dysfunction in patients suffering with
nervous system disorder in the US. Further research should focus
on obtaining more precise estimates using a national level data
to determine trends of neurogenic bladder.
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OBJECTIVES: To evaluate the association between comorbidi-
ties and drug use with the risk of in-hospital fall in adult Chronic
Kidney Disease (CKD) patients. METHODS: A retrospective
case-control study was conducted at a University medical center
between January 1, 1998 and June 30, 2003. To be included as
a case, patients had to experience an in-hospital fall, ≥18 years
of age and, hospitalized for >24 hours. All patients had CKD
deﬁned as a glomerular ﬁltration rate less than 60ml/min on
admission. For every case, a matched control was identiﬁed in a
1 :2 ratio. Cases and controls were matched on CKD, age and
gender. Comorbidities were identiﬁed using ICD-9 CM diagno-
sis codes. Drug utilization was identiﬁed two days before the fall
date for cases and the reference fall date for controls. Statistics
performed were T-tests, chi-square, and conditional logistic
regression using “fall” as the dependent variable and race,
comorbidities and drug groups as covariates. RESULTS: There
were 635 fall cases that met study criteria. The mean age was 68
± 15 years, 54% were female, and 82% were Caucasian. Cases
were more likely to have congestive heart failure (33% vs. 27%),
diabetes (39% vs. 32%), dementia (6% vs. 2%) and pneumonia
(14% vs. 8%) and be receiving antidepressants (29% vs 19%),
antipsychotics (16% vs 13%) and anticonvulsants (15% vs
10%). Compared to controls, cases have multiple comorbidities
(54% vs 43%, p < 0.001) and received multiple drug 
groups (48% vs. 40%, p < 0.002) prior to the fall. Regression
analysis showed that CKD patients with dementia (OR 2.4, p =
0.001) and those receiving antidepressants (OR 1.5, p = 0.001)
and anticonvulsants (OR 1.5, p = 0.008) were more likely to
experience an in-hospital fall. CONCLUSION: The largest
health status risk factor for falling in CKD patients was 
dementia. Drugs associated with falling were antidepressants and
anticonvulsants.
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OBJECTIVE: To examine the economic impact of pharma-
cotherapy (PT) versus non-pharmacologic management (NPM)
among elderly patients with overactive bladder (OAB).
METHODS: Data were obtained from the PharMetrics Patient-
Centric Database on continuously beneﬁt-eligible patients ≥65
years of age diagnosed with OAB between January 2002 and
